Metformin

Metformin labeling carries a lactic-acidosis warning, with risk factors including impaired kidney function, hypoxic illness, excessive alcohol use and certain interacting medicines. Its labeled purpose is glycemic control in type 2 diabetes, not longevity or protection from AAS toxicity.^[1]

• A label warning is not a frequency estimate for appropriately prescribed treatment.

The June 2026 metformin label includes mitochondrial diseases among risk factors for lactic acidosis and states that treatment is not recommended in people with diseases such as MELAS or MIDD.^[1]

• This is labeled risk information. It does not establish a specific interaction with another compound.

Metformin labeling reports cholestatic, hepatocellular and mixed liver injury after marketing. A published case described recurrence after unintended re-exposure, supporting the possibility of idiosyncratic liver injury.^[1][3]

• Voluntary reports and a single case cannot estimate frequency or prove that metformin caused every reported case. This evidence concerns liver injury, while lactic-acidosis risk in hepatic impairment is a separate labeled concern.

In the 4.3-year HOME trial in insulin-treated adults with type 2 diabetes, metformin lowered vitamin B12 concentrations and increased biochemical B12 deficiency compared with placebo. The overall between-group homocysteine increase was not statistically significant.^[4]

• Attrition, assay exclusions and supplementation affected the analysis. Biochemical deficiency does not itself establish neuropathy or a mandatory monitoring interval.

A one-month trial randomized 74 men with newly diagnosed type 2 diabetes after intensive insulin normalized their glucose. Among 70 analyzed, adding metformin lowered serum testosterone compared with continued insulin alone. The report provided no LH, FSH or semen outcomes.^[5]

• The trial was open-label, selected insulin-treated men and excluded four participants after randomization. It does not establish infertility, suppression like that caused by anabolic steroids, or a recovery timeline; erectile-function change did not differ.

Metformin is eliminated unchanged in urine. Its label reports a plasma elimination half-life of about 6.2 hours and a blood half-life of about 17.6 hours; a pharmacokinetic review reports about 5 hours over repeated-dose intervals, with a longer late phase. These estimates describe different measurements, and reduced kidney function prolongs elimination.^[1][2]

• These values do not establish a universal duration of action or washout timetable. Formulation, sampling schedule, blood versus plasma measurement and kidney function matter.

In the MASTERS trial, older adults receiving metformin during resistance training gained less lean mass by DXA and less normal-density thigh muscle area by CT than those receiving placebo. Between-group strength differences were not statistically significant.^[6]

• 109 participants were randomized and 94 completed the trial. Selected adults aged 65 or older, attrition and protocol deviations limit generalization to young athletes; there was no sedentary comparison.
• The registered primary outcome, type II muscle-fiber area, did not differ. The mass and area findings concern additional outcomes with smaller analysis groups.

In a 12-week aerobic-training study of older adults with diabetes risk factors, metformin attenuated improvement in an oral-glucose-test estimate of insulin sensitivity. The between-group difference in aerobic fitness change was not statistically significant.^[7]

• The study was small, outcome denominators varied and there was no metformin-only arm. These results do not predict every individual training response.

In a small crossover trial completed by 14 healthy, physically active men, a single metformin exposure did not significantly improve performance in either of two repeated agility tests compared with placebo.^[8]

• This task-specific acute result does not establish a general benefit, absence of every possible exercise effect, or long-term safety.

In a crossover study of 15 healthy, lean men, metformin did not significantly change self-selected cycling intensity. Perceived exertion was higher during a separate fixed-intensity exercise bout, while measured peak oxygen consumption did not differ.^[9]

• The small male sample, multiple comparisons and subjective exertion measure limit interpretation. The exertion difference has uncertain clinical importance and does not demonstrate lactic acidosis.

In a 13-week diabetes pilot, gastrointestinal symptoms led to reduced berberine exposure during add-on treatment; affected participants included people also taking metformin or acarbose. These coexposures were pooled and lacked a matching control group, so the study does not isolate a metformin-specific interaction.^[10]

• Observed symptoms during varied combination treatments do not establish causality or the additional risk of the named pair.
• Research exposure changes are not treatment or dose-spacing instructions.